Erosion risks

• Private label and value-brand trading down
• Brand damage from quality/safety issues
• Feature parity reducing differentiation (e.g., cleaners, OTC remedies)

Leading indicators

• Price/mix vs volume trend by quarter
• Brand equity investment (BEI) as % of net revenue
• Market share trend in top Category Market Units (CMUs)

Counterarguments

• Many categories have low switching costs; promotion can move share quickly
• Large rivals (P&G, Unilever) can match marketing spend and shelf presence

Erosion risks

• Regulatory changes can tighten claims or increase compliance costs
• Competitors can obtain similar approvals over time
• Litigation/regulatory scrutiny of marketing claims

Leading indicators

• Regulatory actions affecting antimicrobial/OTC claims (US/EU)
• Product recall frequency and severity
• Time-to-market for new product registrations

Counterarguments

• Regulatory compliance is necessary but not sufficient; approvals are replicable for scaled competitors
• Innovation can be copied once regulatory pathways are proven

Erosion risks

• Portfolio simplification can reduce cross-brand synergies
• Digital-first challengers reduce the advantage of incumbent marketing scale
• Retailer power and e-commerce platforms can compress brand advantages

Leading indicators

• SG&A efficiency and fixed-cost % of net revenue
• Share of revenue from 'Powerbrands' (portfolio concentration)
• Incremental ROI on marketing and innovation launches

Counterarguments

• Scale can become bureaucracy; smaller brands can innovate faster
• Marketing scale is less defensible if consumers switch based on price/promotion

Erosion risks

• Litigation outcomes and reputational damage
• Product recalls or quality incidents
• Share loss to private label or competitors post-supply normalization

Leading indicators

• Non-WIC and total value market share trends
• Regulatory inspection outcomes and remediation costs
• Litigation developments and settlement reserves

Counterarguments

• Medical recommendation effects can be diluted by aggressive competitor promotion and pricing
• Trust can unwind quickly after safety events in infant categories

Erosion risks

• Hospital/pediatric guidance shifts following clinical controversies
• Greater acceptance of store-brand formula and switching
• Increased transparency/standardization reducing perceived differences

Leading indicators

• Hospital sampling and paediatrician engagement metrics (if disclosed)
• Formula switching rates and churn proxies
• Share by channel (hospital, pharmacy, mass)

Counterarguments

• Regulators and medical bodies often emphasize nutritional equivalence, reducing 'qualification' advantages
• Caregivers can switch based on price, availability, or infant tolerance

Erosion risks

• Tighter regulation increases costs and disrupts supply
• Competitors can also invest to meet standards, reducing differentiation
• Regulatory findings can force plant shutdowns or recalls

Leading indicators

• Capex and remediation spending tied to regulatory requirements
• Supply disruptions (plant downtime, inventory fill rates)
• Regulatory enforcement actions in key markets

Counterarguments

• Regulation is an industry-wide constraint rather than a durable competitive edge
• Compliance spend may depress returns versus less-regulated categories